CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells
详细信息 查看全文
- 作者：Yang Lia ; Yi-fei Lic ; Chong-zhan Sia ; Yu-hui Zhub ; Yan Jinb ; Tong-tong Zhua ; Ming-yuan Liua ; d ; Guang-yao Liua ; myth03171@yeah.net" class="auth_mail" title="E-mail the corresponding author
- 关键词：CCL21 ; IL21 ; Oncolytic adenoviruses ; Tissue-specific promoter ; Combination gene therapy
- 刊名：Virus Research
- 出版年：2016
- 出版时间：15 July 2016
- 年：2016
- 卷：220
- 期：Complete
- 页码：172-178
- 全文大小：1336 K
文摘
- •
We constructed a CCL21/IL21 co-expression CRAds (conditionally replicating adenoviruses) based on AdEasy system. The Ad-CCL21-IL21 contains three plasmids: pGTE-IL21, pShuttle-CMV-CCL21 and AdEasy-1, Escherichia coli strain BJ5183, and packaging cell line 293.
- •
Ad-CCL21-IL21 could selectively replicate in TERT-positive tumor cells, because the plasmid pGTE-IL21 contained the promoter of telomerase reverse transcriptase (TERTp).
- •
Our results showed that Ad-CCL21-IL21 induced oncolytic effects and tumor-specific cytotoxicity of cytotoxic T lymphocytes (CTLs) in vitro.
- •
This study suggests that Ad-CCL21-IL21 can induce antitumor immune response in tumor tissues and this platform can be modified to generate novel CRAds with other transgenes.